Market closedNon-fractional

Trevi Therapeutics/TRVI

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Trevi Therapeutics

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Ticker

TRVI

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

New Haven, United States

Employees

25

TRVI Metrics

BasicAdvanced
$182M
Market cap
-
P/E ratio
-$0.34
EPS
0.91
Beta
-
Dividend rate
$182M
0.91
14.55
13.802
1.312
1.757
-237.68%
-24.56%
-38.57%
2.47
2.47
-7.519
-2.36%
-42.40%

What the Analysts think about TRVI

Analyst Ratings

Majority rating from 6 analysts.
Buy

TRVI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
39.74%
Profit margin
0.00%
NaN%

TRVI Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 25.00%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.07
-$0.08
-$0.08
-$0.11
-
Expected
-$0.09
-$0.09
-$0.09
-$0.09
-$0.11
Surprise
-17.65%
-12.73%
-12.73%
25.00%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Trevi Therapeutics stock?

Trevi Therapeutics (TRVI) has a market cap of $182M as of July 06, 2024.

What is the P/E ratio for Trevi Therapeutics stock?

The price to earnings (P/E) ratio for Trevi Therapeutics (TRVI) stock is 0 as of July 06, 2024.

Does Trevi Therapeutics stock pay dividends?

No, Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Trevi Therapeutics dividend payment date?

Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders.

What is the beta indicator for Trevi Therapeutics?

Trevi Therapeutics (TRVI) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Trevi Therapeutics stock

Buy or sell Trevi Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing